WASHINGTON — The Trump administration wants to modernize the federal guidelines for companies that sell made-to-order DNA in hopes of keeping dangerous genetic material — like smallpox or the Ebola virus — out of the hands of malicious potential customers, federal officials confirmed to STAT this week.

The administration’s work is still in early stages, and it’s too soon to tell whether or how the government will make the guidelines more stringent, as companies and experts in the space have called for. Right now, the Department of Health and Human Services is kicking off “a broad interagency effort to review the guidance and make any necessary changes to reflect the evolving technological landscape,” said Theresa Lawrence, a director in HHS’s Office of the Assistant Secretary for Preparedness and Response.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy